Recursion is advancing REC-617, a promising reversible, non-covalent CDK7 inhibitor, showing potential in treating advanced solid tumors with positive interim phase 1 data. Read more here.
Researchers from the Francis Crick Institute have found that some particularly aggressive lung cancer cells can develop their ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback